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ABSTRACT
Buccal drug delivery especially refers to the delivery of drugs through the buccal mucosal membrane lining of the oral cavity. For geriatric and 
pediatric patients who undergo difficulties in swallowing conventional oral solid dosage forms, the buccal film is a better alternative. The buccal film 
is appropriate for the drugs which experience high first-pass metabolism and is used for enhancing bioavailability with reducing dosing frequency to 
mouth plasma peak levels, which thus limit side-effects and make it cost-effective. It enhances the efficacy of API in the oral cavity after the contact 
with less saliva as contrasted to tablets, without chewing and no need for water for administration. This review briefly describes the advantages 
and limitations of buccal film, an anatomical structure of oral mucosa, highlighting the mechanisms of drug permeation, formulation technologies, 
methodology in evaluating buccal film, and recent advances of the buccal film as a tool for drug delivery for various treatments.
Keywords: Buccal film, Oral mucosal drug delivery system, Bioavailability enhancement.
INTRODUCTION
Among the various routes of drug delivery, oral-mucosal drug delivery 
offers distinct advantages as buccal mucosa is the most suited for local, 
as well as systemic delivery of drugs [1]. The buccal film is a drug 
delivery system that has rapidly gained acceptance as a new way of drug 
administration, improved safety and efficacy of drug molecule, and the 
enhanced onset of action [2]. The buccal film is an elegant and effective 
dosage form with enhanced bioavailability when compared to other 
dosage forms, as it by-passes the hepatic first-pass metabolism [3]. The 
site of drug administration in oral-mucosa is subdivided into buccal 
and sublingual mucosa [4]. The order of permeability of the oral cavity 
is given as sublingual > buccal > palatal [5]. The buccal mucosa being 
comparatively immobile mucosa than sublingual mucosa and readily 
available, it makes it more advantageous for retentive systems used 
for oral-mucosal drug delivery [6]. The buccal film may be preferred 
over a buccal tablet, in terms of comfort and flexibility [7]. The buccal 
film is well known that the absorption of therapeutic compounds 
from the oral-mucosa provides direct entry of a drug into systemic 
circulation through the jugular vein [8]. The advantages of buccal 
film are low cost,ease of administration,high patience compliance [9]. 
Active pharmaceutical ingredients (API), various polymer, plasticizer, 
saliva stimulating agent, permeation enhancers, sweeteners, flavoring 
agents, preservatives, and color, are used in formulating buccal film. 
The buccal film is essentially positioned on oral mucosal tissues, which 
is quickly wet by saliva in the mouth; the film is quickly hydrated and 
follows on to the site of application [10]. The main property of buccal 
film is that, because of the large surface area of the film, it allows quick 
wetting of the film which increase the absorption of the drug quickly as 
compared to the tablets. The buccal mucosa is rich with blood supply, 
which acts as a perfect and fast site for the absorption of drug [11].
ADVANTAGES OF BUCCAL FILM
The advantages of buccal films are as follows:
1.	 The	buccal	film	shows	a	comparatively	rapid	onset	of	action	with	
lesser side effects than other routes of administration [12].
2. Flexible and portable so provide ease in transportation during 
handling and storage [13].
3. Accurate dose administration [13].
4. Enhanced stability and safety [14].
5. As compared to the intravenous delivery system, mucosal delivery 
systems have the easy application of dosage forms with no pain on 
administration leading to improved patient compliance [15].
6.	 Avoids	 the	 first-pass	metabolism	and	hence	the	drug	will	not	get	
exposed	to	the	gastrointestinal	fluid	[16].
7. By incorporating mucoadhesive polymers of “SR” grade, this system 
can also attain sustained drug delivery [17].
8. Low dose frequency due to longer duration of residence time along 
with controlled drug release [18].
9.	 Due	to	direct	contact	and	adhesion	buccal	film	remains	for	a	long	
period at the application site and thus increases bioavailability using 
a low concentration of API [19].
10. Environmental factors such as acidic and degradation environment found 
in	the	oral	drug	delivery	can	be	evaded	by	buccal	film	dosage	form	[20].
11. Appropriate dosage form for geriatric and pediatric patients 
experiencing	difficulty	 in	 swallowing	or	nauseating	and	patients	
who are mentally ill or physically disabled [21].
DISADVANTAGES OF BUCCAL FILMS
There are numerous advantages of the buccal film but with few 
disadvantages lead to a main challenging formulation.
1. Barrier properties of the oral mucosa [22].
2. Restriction of drinking and eating [23].
3. Drugs with a lower dose requirement can be administered [23].
4. Dilution of drug and swallowing of the formulation due to vigorous 
secretion of saliva [24].
ANATOMY AND PHYSIOLOGY OF ORAL MUCOSA
The oral mucosa acts as an important route for the delivery of drugs. The 
oral cavity has been diagrammatically represented, as shown in Fig. 1. 
The oral cavity presents the total surface area of about 100 cm2, that 
is, lined by mucus membranes [25]. The oral cavity consists of about 
one-third of the buccal surface of 0.5 mm thickness epithelium [26]. 
Following are several sites that have been used for drug administration 





5. Gingival region 
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The oral mucosal cavity comprises the multilayered epithelial tissues 
that are additionally covered by mucus. Here is a basal membrane 
present inward to the epithelial tissues. Inside the basal membrane, 
there is a layer of connective tissue called lamina propria. The lamina 
propria provides a mechanical support function. After this, the sub-
mucosal part begins. It contains the different blood vessels as well 
as nerves from the central nervous system. The cross-section of the 
buccal mucosa is represented in Fig. 2. The sub-mucosal part provides 
the highest vascularity for the complete absorption of the drugs. The 
human oral mucosa contains both keratinized epithelium (found in the 
gingival and part of the hard palate) and the non-keratinized epithelium 
(found on the surface of the distensible lining mucosa, of the soft palate, 
floor of the mouth, lips, and cheek) [25].
The buccal region is the part of the mouth, limited anteriorly, and 
laterally by the lips and cheeks, posteriorly and medially by the teeth as 
well as gums, or above and below by the impressions of mucosa from 
the lips and cheeks to the gums. Buccal mucosa’s essential role is similar 
to the skin, which is protection of underlying structures from foreign 
agents [27]. The permeability of the buccal mucosa is 4–4000 times 
greater than that of the skin approximately. The order of permeability 
of the oral mucosa is sublingual>buccal> palatal which relies on relative 
thickness and level of keratinization [26].
The mucus layer
To the mucosal epithelial surface a clear and viscid secretion which is 
thin, continuous gel covers are adherent called mucus. In the human, 
the mean thickness of this layer varies from around 50 to 450 µm. The 
goblet cells lining the epithelial or by extra-ordinary exocrine glands 
that secreted mucus. The specific composition of the mucus layer 
differs significantly relying on the species, the anatomical location, and 
the pathophysiological state [28].
However, it has the following general composition:
Components Percentage
Water 95
Glycoproteins and lipids 0.5–5
Mineral salts 1
Free proteins 0.5–1
MECHANISM OF BUCCAL FILM
Buccal film when, simply positioned on the patient’s oral-buccal mucosal 
tissue, instantly become wets by saliva. Due to the presence of hydrophilic 
polymers and other excipients, the film quickly hydrates, dissolves, and 
releases the medication, thus ensuring the absorption of medicament [29].
Fig. 2: Cross-sectional view of buccal mucosa. Adapted from Gureja et al. Bucco adhesive drug delivery system. Available at (https://www.
pharmatutor.org/articles/bucco-adhesive-drug-delivery-system). Copyright permission obtained from website of pharmatutor (https://
www.pharmatutor.org)
Fig. 1: Anatomy of oral cavity. Adapted from Kraan et al. 2014, Buccal and Sublingual Vaccine Delivery. Journal of Controlled 
Release.190:580-92. Copyright permission obtained under CC-BY-NC-ND License. (https://creativecommons.org/licenses/by-nc-nd/3.0/)
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Drug absorption pathways




The absorption capability of the buccal mucosa is affected by the lipid 
solubility and molecular weight of the diffusant. Absorption of a certain 
drug through buccal mucosa is found to increase when carrier pH is 
lowered and decreased by an increase in pH [30].
Buccal film dosage form release mechanism
Buccal film dosage form further divided into three types they are as 
follows:
1. Type I: Single layer device suffers from drug loss due to 
multidirectional	drug	release	on	significant	swallowing.
2. Type II: Impermeable backing layer is superimposed on the top of 
the drug-loaded bio-adhesive layer prevents loss from the top surface 
in the oral cavity. 
3. Type III: Unidirectional drug release can be achieved by coating 
every face of the dosage form except the one that is in contact with 
buccal mucosa. Since the drug release from one side will minimize 
drug loss [27]. 
Theories of bio-adhesion








Among the above mention theories, adsorption theory plays an 
important role in the adhesion of the buccal film mechanism.
Adsorption theory
As per absorption theory, after initial contact between the buccal 
mucosal surface and the material adheres to it has their own surface 
energy.
Chemical bonds involves following forces:
1. Primary chemical bond: Such as covalent nature, this is undesirable 
because higher strength may result in a permanent bond. 
2. Secondary chemical bond: Different forces of attraction includes 
electrostatic forces, Van der Waals forces, hydrogen, and hydrophobic 
bonding, which are weak in nature, thus produces a semi-permanent 
bond [28].
IDEAL CHARACTERISTICS OF BUCCAL FILM
1. All degradation products and polymers should not be toxic, 
poisonous, and irritant and must be free from impurities [31].
2. It should have good spread ability, swelling, wetting, solubility, 
biodegradability, viscoelastic properties, and biocompatible pH 
range [32].
3. It should have an appropriate shelf life without decomposition on 
storage [33].
4. It should adhere quickly to the buccal mucosa and should have good 
mechanical strength [34].
5. It should have adequate patient compliance without obstructing 
normal functioning such as talking, eating, and drinking [34].
6. Drugs should release in a controlled manner [34].
7. Unidirectional passage of drug release should be provided toward 
the mucosa [35].
8. The rate and extent of drug absorption should be facilitated [35].
9. The dose should be lower than 20 mg with low molecular weight [36].
10. It should have good stability in water and saliva [36].
11. It should have the ability to permeate oral mucosal tissue [36].
12. It should not have a bitter or unpleasant taste [37].
COMPOSITION OF BUCCAL FILM
Active ingredients
The buccal film technology has the potential for delivery of 
variety of APIs [38]. Active pharmaceutical substances can be 
from any Biopharmaceutical Classification System (BCS) class of 
pharmaceutically active substances that can be given either orally or 
even by buccal mucosa. To make a successful and effective formulation 
the drug to be administered should be <20 mg daily [39]. Table 1 gives 
a list of marketed buccal films.
Plasticizer
Plasticizers are very critical for the formulation of a buccal drug delivery 
system [42]. They help by improving the mechanical properties of the 
buccal film which includes tensile strength, elongation of the films 
while additionally provide other advantages such as a reduction in the 
brittleness of the film and enhanced flexibility along with an increment 
in the flow property of the polymer and slashing of the glass transition 
temperature of the polymer. The amount of the polymer used can be 
remodeled which subsequently alters the properties of the final film so 
obtained. Examples of plasticizers include glycerin, sorbitol, propylene 
glycol, polyethylene glycol, tri-acetin, dibutyl phthalate, tri-ethyl-
citrate, acetyl tri-ethyl-citrate, and other citrate esters. The amount of 
the plasticizer to be used can vary from about 0 to 20% w/w of the 
dry polymer weight. Plasticizers also upgrade the folding capacity of 
the final buccal films [43]. Glycerin was employed as a plasticizer in 
preparation of fast dissolving buccal films containing a solid dispersion 
of isradipine [44].
Sweetening agents
Sweeteners play a pivotal role in the pharmaceutical preparations 
which have an aim of either disintegration or dissolution in the mouth. 
The traditional sources of sweeteners are, namely, sucrose, dextrose, 
fructose, glucose, liquid glucose, and iso-maltose. Fructose is a versatile 
sweetener employed in industries as sweetness of fructose is recognized 
quickly in the mouth when compared against sucrose and dextrose and 
while it is more sweeter than sorbitol and mannitol as well as polyhydric 
alcohols such as sorbitol and mannitol. Polyhydric alcohols offer reduced 
carcinogenic chances and lack the bitter after taste which is an important 
parameter in preparation of oral preparations [45]. Herbal sweeteners 
can also be used for example being Rebiana, derived from the plant Stevia 
rebaudiana (South American plant) having more than 200–300 times 
Table 1: List of marketed buccal films
Active drugs Uses Manufacturer Reference
Fentanyl Citrate Opioid analgesic Meda Pharmaceuticals, Inc Satheesh Madhav et al. 2012 [39].
Buprenorphine Opioid analgesic Bio delivery Sciences International Satheesh Madhav et al. 2012 [39].
Loratadine Anti-histaminic Hughes medical corp. Dahiya et al. 2009 [40].
Donepezil Alzheimer’s Labtec Dahiya et al. 2009 [40].
Simethicone Bloating, belching Novartis Dahiya et al. 2009 [40].
Phenylephrine Nasal decongestant Pfizer Dahiya et al. 2009 [40].
Menthol Canker sore Cooling sensation in throat pain Innozen Dahiya et al. 2009 [40]. Canker sore
Choline Salicylate To treat aphthous lesions Daněk	et al. 2017 [41].
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sweetness of sucrose [46]. Artificial sweetener such as Saccharin Sodium 
was also employed in formulation of buccal film [47].
Surfactants
Surfactants are utilized as solubilizing or wetting or dispersing agents 
with the aim that the film gets melted within seconds and liberate 
the active agent instantly. Surfactants also enhance the solubility of 
poorly soluble drugs in fast-dissolving buccal films. Examples include 
polaxamer407, sodium lauryl sulfate, benzalkonium chloride, tweens, 
and spans [48].
Flavoring agent
Flavoring agents are used to providing flavor to the product which is 
also a factor of patient compliance. Flavoring agents can be chosen from 
a wide variety of materials including synthetic flavor oils, oleoresins, 
and extract obtained from multiple parts of the plants such as leaves, 
fruits, and flowers. Flavors can be employed solo or in conjunction 
with each other. Peppermint oil, cinnamon oil, spearmint oil, and oil 
of nutmeg are examples of flavor oils, whereas vanilla, cocoa, coffee, 
chocolate, and citrus are fruity flavors derived from fruits. Flavors can 
be used alone or in one or more combination. The quantity of flavor 
required to hide the taste of the original drug depends on the flavor 
category and its power. Mostly, a maximum of 10% w/w flavors is 
added in the buccal film formulations. To enhance the flavor strength as 
well as to increase the pleasant sensation of the product, cooling agents 
such as mono-methyl succinate can be added [49,50].
Coloring agent
The patient compliance of oral disintegrating films relies on the 
flavoring agent incorporated into it which, in turn, is dependent on the 
category of drug present in the formulation, for example, Peppermint 
oil and cinnamon oil [51].
Saliva stimulating agent
The main aim of saliva stimulating agent is to increase the production 
of saliva and help dissolve the buccal film faster. The concentrations in 
which they are used ranges from 2% to 6% [52].
Backing membrane
The backing membrane is an impermeable covering that has been 
attached to one side of the buccal film so that the drug is allowed to 
release into the oral cavity only in one direction and it also prevents 
leakage of the drug from the other side. 1% Ethyl cellulose was used as 
a backing membrane in preparation of an opioid drug [53].
Polymers
Many polymers are within easy reach for the production of fast 
dissolving buccal films. The polymers can be used exclusively or in 
conjunction to give the required film properties. The film procured 
should be strong enough to withstand any damage while handling 
or during transportation. The robustness of the strip hangs on the 
type of polymer and the concentration used in the formulation. The 
many polymers employed in production fast-dissolving films include 
cellulose or cellulose derivatives, pullulan, gelatin, hydroxyl propyl 
methyl cellulose (HPMC), hydroxyl ethyl cellulose (HEC), hydroxyl 
propyl cellulose (HPC), polyvinyl pyrrolidone (PVP), carboxymethyl 
cellulose (CMC), polyvinyl alcohol (PVA), sodium alginate, xanthine 
gum, tragacanth gum, guar gum, acacia gum, methyl methacrylate 
(MMA) copolymer, and hypromellose are most regularly employed 
for the production of fast-dissolving films. Pullulan is a natural 
polymer derived from non-animal origin and has no need for chemical 
modification up to 50–80% w/w of pullulan can be substituted by starch 
in the preparation of fast dissolving films without wasting the desired 
properties of pullulan. Combining microcrystalline cellulose (MCC) 
and malt dextrin can also be employed to make fast dissolving films. 
Investigation of many polymers for application in the production of oral 
fast-dissolving strips was done. Different polymers such as HPMC E15, 
HPMC K4M, HPMC E5, PVP, PVA, gelatin, Eudragit RL100, and pullulan 
were used to make fast-dissolving buccal films; by employing solvent 
casting method. Conclusions proved that pullulan reigns supreme for 
oral fast-dissolving strips [54]. Klucel HXF Pharm (Hydroxypropyl 
cellulose) was employed as a mucoadhesive polymer in formulating a 
buccal film comprising a polyphenol [55].
METHODS OF PREPARATION OF BUCCAL FILMS
The following methods are used in the preparation of buccal films:
Semisolid casting
 The semisolid casting method comprises the below-given steps:
1.	 A	water-soluble	film-forming	polymer	solution	is	prepared.	
2. The resulting solution so formed is poured into a solution of acid-
insoluble polymer (e.g., cellulose acetate phthalate, and cellulose 
acetate butyrate).




should be approximately 0.015–0.05 in. The proportion of the acid-
insoluble	polymer	to	film-forming	polymer	should	be	1:4	[56].
Solid dispersion extrusion
The expression of solid dispersions relates to the dispersion of one or 
more active ingredients in a chemically inactive carrier in a solid-state 
in the attendance of amorphous hydrophilic polymers.
1. The drug is dissolved in a suitable liquid solvent.
2. Then, the solution is then added into liquid polyethylene glycol, which 
is achieved when heated above 70°C.
3.	 Ultimately	 the	solid	dispersions	are	molded	 into	 the	 films	by	 the	
employment of dies.
Some safeguard measures must be taken care of while using this 
method such as the chosen solvent or dissolved drug may immiscible 
with liquid polyethylene glycol and polymorphic form of the drug 
precipitated in the solid dispersion may get altered by the liquid solvent 
used [57].
Solvent casting method
The solvent casting method is most commonly used for the production 
of buccal films. This procedure involves the below-given steps:
1. Water-soluble components (polymers) are dissolved in water to form 
a single viscous solution.
2. API and other excipients are dissolved in an appropriate solvent to 




 In this technique, the film is produced by making a pre-mix, followed 
by the incorporation of an active ingredient and subsequently the 
formation of a film. 
1.	 Produce	a	pre-mix	comprising	a	film-forming	polymer,	polar	solvent,	
and other additives with exception of a drug.
2. Incorporate pre mix to master batch feed tank.
3. Transfer it by a 1st metering pump and control valve to one or all of 
the mixers.
4. Add the desired quantity of the drug to the desired mixer.
5. Mix the drug with master batch pre-mix to give a homogenous matrix.
6.	 Then,	a	fixed	quantity	of	uniform	matrix	is	then	added	to	the	pan	
utilizing the 2nd metering pump.
7.	 The	film	is	ultimately	produced	on	the	base	material	and	transported	
away utilizing a support roller.
8.	 The	wet	film	is	then	dehydrated	by	supervised	bottom	drying	[65].
BUCCAL FILMS USED IN FORMULATION OF SOLUBLE AND 
INSOLUBLE DRUGS
Bioadhesive buccal film of ketoprofen was produced using an 
amalgamation of various polymers. The conclusions revealed that 
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in vivo in vitro (IVIVC) was about 0.975 thus demonstrating a good link 
between in vivo and in vitro tests. The ex vivo release studies expressed 
ketoprofen attaining the therapeutic concentration in the plasma 
after about 1 h. In regards to mucoadhesion ability, the batch was 
manufactured using polycarbophil as the polymer exhibited the highest 
mucoadhesion power of about 6½ [66]. A buccal film for delivery of 
anti-diabetic drug glimepiride was formulated using a novel nanocarrier 
armed with D-a-tocopherol polyethylene glycol 1000 succinate micelles 
(TPGS) also known as Vitamin E in common terms. The film was 
compared with a reference film of glimepiride (GMD) with the absence 
of the nanocarrier which was subsequently labeled with a fluorescent 
compound. The results revealed that the mathematical design so used 
did not fail to boost the factors that increase the liberation of GMD 
in a single direction from the transmucosal film packed with TPGS 
micelles in a controlled and foreseen manner. The boosted formulation 
demonstrated that the diffusion of GMD from the film was preferable 
towards TPGS micelles. The boosted one direction release of GMD 
transmucosal film was about 93.9% in 6 h compared to 60.41% of GMD 
release from the standard GMD film. This conclusion was established 
by its property to transport the GMD across the buccal mucosa, thereby 
showed by the ferocity of fluorescence with the fluorescence-labeled 
upgraded formulation [67]. Chlorzoxazone was modified by solid 
dispersion technique to refine its solubility and then incorporated it in 
buccal film. The findings revealed that the drug chlorzoxazone when 
formulated by a solid dispersion method showed greater dissolution 
and sustained release than the real mixture of the same drug and 
polymer HPMC K4 M [68]. A buccal film of Enalapril Maleate armed in a 
pullulan buccal film was formulated. The experiment of in vitro release 
profile of enalapril maleate fast-dissolving film and enalapril maleate 
tablets were performed in buffer solution (pH 6.8) and water. The 
findings revealed that after the elemental 5 min of the dissolution test, 
the polymeric film liberated 100.30% of the enalapril maleate into the 
buffer solution and 98.31% into water. Under matching conditions, the 
enalapril maleate from tablets showed a release of 5.1% into the buffer 
solution and 4.8% into water. These outcomes of this experiment give 
proof to both the experimental conditions of performing the in vitro 
dissolution test, as well as the proposal to employ these mucoadhesive 
buccal films for enalapril maleate administration [69]. Olmesartan 
Medoxomil (OMX) mucoadhesive buccal film was formulated where 
in the outcomes of the experiment revealed that therapeutic levels 
of OMX can be given through the buccal route as well as the films 
exhibited sustained release over more than 7 h. The study concluded 
that these erodible mucoadhesive buccal films comprising Olmesartan 
can be very optimistic for fruitful doses to systemic circulation as well 
as avoiding the first-pass metabolism thus increasing its half-life [70]. 
Production and assessment of buccal films containing prototype 
drug of paracetamol as soluble and indomethacin as insoluble drug 
individually by employing carrageenan as the base and different grades 
of polyethylene glycol. The results revealed that the transformation of 
crystalline drugs to the amorphous form in the course of film formation 
as well as the film matrix exhibited the property to conserve the two 
prototype drugs in a stable amorphous form throughout the storage 
period of over 12 months. The films showed perfect release patterns 
within acceptable periods, after swelling and diffusion of the polymer 
matrix, under settings representing those of saliva [71].
EVALUATION OF BUCCAL FILM
Weight variation
A calibrated weighing balance was used for weighing buccal film. Each 
film is weighed individually and calculated. The average weight of all 
films is calculated and the actual weight of the film is analyzed [72]. 
Thickness
A calibrated micrometer screw gauge was used for evaluation of 
the thickness of the buccal film. Five different points on the film are 
measured (four on the corners and one in the center) and mean 
thickness is calibrated. This step is important to ensure the uniformity 
of thickness as well as accurate dosing in the film due to their 
correlation [73].
Tensile strength
The property of film that requires load causing deformation and 
finally failure of a film is called tensile strength. Two clamps spaced 
at equidistance are position in such a way that film strips are placed 
in between them. By applying load at rupture and knowing the cross-
sectional area of fractured film, a tensile film can be calculated by the 
following equation [74]:
Tensile strength (N/mm2) = Breaking force (N)/Cross-sectional area of 
sample (mm2).
Surface pH
For determination of surface pH, 2% w/v agar in isotonic phosphate 
buffer pH 6.8 was dissolved and poured into the Petri dish for 
preparation of agar plate and was gelled at room temperature. Buccal 
films were placed on the surface of the agar plate for 2 h until they swell 
completely. pH indicator paper was used for measuring surface pH after 
90s change in color was observed comparing it with a standard color 
scale [75].
Folding endurance
For the measurement of folding endurance, three films were cut into 
appropriate size. By folding one film at the same place repeatedly 
or by folding up to 300 times till it breaks, folding endurance can be 
determined. The value of folding endurance can be identified when the 
film does not break even after folding the film multiple times [76].
Drug content uniformity
Drug uniformity was determined by dissolving 5 films weighed 
previously in 100 ml of isotonic phosphate buffer pH 6.8 with the help 
of a magnetic stirrer for 2 h. Further, this solution was filtered with 
Whatman filter paper, and after suitable dilution, drug was analyzed 
using a spectrophotometer [77].
Fig. 3: Solvent casting method for manufacturing of buccal film. Adapted from Reference [64]. Copyright permission obtained under 
creative commons (CCBY) license (http://creativecommons.org/licenses/by/4.0/)
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Percentage moisture loss test
Two films of 2 × 2 cm2 were placed in the desiccator with anhydrous 
calcium chloride, percentage moisture loss was determined. The films 
were taken out after 3 days and were weighed. Using the formula below, 
percentage moisture loss was calculated [78].
Percentage Moisture Loss= [(Initial weight – Final weight) / Initial 
weight] × 100 
Percentage moisture uptake
Films were kept in the desiccator at room temperature for 24 h with 
saturated potassium chloride solution and maintained 84% relative 
humidity. The films were taken out and weighed after 24 h. Percentage 
of moisture uptake can be calculated by the following formula [78].
Percentage moisture uptake = [(Final weight – Initial weight) / Initial 
weight] × 100
Swelling index
Each buccal film was weighed individually (W1) and placed in the Petri 
dish separately containing phosphate buffer pH 6.8. Buccal films were 
removed using filter paper so that excess surface water is separated 
from the Petri dish and weighed again (W2). Swelling index (S1) was 
calculated using the formula: [79]
SI = (W2 – W1) / W1
Where;
SI = Swelling index
W2 = Final weight
W1 = Initial weight
In vitro disintegrating time
It can be visually analyzed in a Petri dish with 2 ml of distilled water 
by swirling after every 10 s. The time taken by the film to disintegrate 
or break is noted and recorded as the in vitro disintegration time [80].
In vitro dissolution study
USP type II apparatus (Basket type apparatus) was used for dissolution 
studies with pH 6.8 buffer (50 ml) as a dissolution medium at 37°C 
temperature and speed at 50 rpm. 1ml of sample solution was 
withdrawn and equilibrated with a fresh dissolution medium. Whatman 
filter paper of 0.45 µm was used to filter the buccal films and API was 
analyzed spectrophotometrically at λmax [81].
In vitro drug release
Franz diffusion cell assembly was used for in vitro drug release 
studies. It consists of two compartments, one of the receptor chambers 
containing a buffer solution of pH 6.8 and other donor compartment 
containing 10 mg of the drug. A dialysis membrane (Mol. Wt 12000–
14000) which was previously soaked for 2 h in receptor medium 
was placed in between these compartments to separate it from each 
other. To avoid disruption in the ongoing process, it was ensured that 
no air bubbles were seen between the membrane and liquid surface. 
During the entire process, the temperature was maintained at 37°C by 
circulating water bath. At a specific time interval, till 8 h 0.5 ml of the 
sample was withdrawn from the receptor chamber and filled with fresh 
buffer. Suitable dilution was carried out and the amount of drug release 
was spectroscopically analyzed. The flux value was identified by the 
following formula [82]:
Flux = Amount of drug released (mg)/Time (hr) × Area (cm2)
Ex vivo mucoadhesion time
For determining the mucoadhesion time, the buccal film is applied to 
the fresh buccal mucosa of sheep or rabbit which is tied on a glass slide. 
The buccal film is wetted with a drop of phosphate buffer pH 6.8 and 
applied with a mild force on the buccal mucosa for 30 s using fingertips. 
In a beaker containing 200 ml of phosphate buffer pH 6.8, the glass 
slide is kept at 37°C ± 1°C. To simulate the environment of the buccal 
cavity, a 50 rpm stirring speed is applied after 2 min and film adhesion 
is regulated for 24 h. The time taken for visible changes in shape and 
color is recorded along with the collapsing time of the film [45].
Ex vivo permeation studies
For performing permeation studies modified Franz diffusion cell was 
utilized. Two compartments, one of the donor compartments and other 
receptor compartments were seen of 25 ml capacity. To maintain the 
temperature at 37°C, the receptor compartment was enclosed with a 
water jacket consisting of 23 ml of pH 6.6 phosphate buffer. The separated 
buccal epithelium was mounted between the two chambers and the 
entire assembly was placed on a magnetic stirrer by putting a magnetic 
bead coated with Teflon. The buccal film was kept aside for stabilization 
after which 1 ml of the sample was withdrawn at regular intervals and 
was suitably diluted for analyzing it spectrophotometrically [83].
Stability studies
Stability studies are undertaken for analyzing any changes during the 
storage of any formulation. For 3 months, all the formulations were 
kept in triplicate at 40°C ± 2°C and 75°C ± 5% RH in stability chambers. 
By analyzing their folding endurance, drug content, and in vitro drug 
release, stability studies were evaluated [84].
PACKAGING OF BUCCAL FILM
At most care and precautions should be carried out while selecting 
packaging material to protect the integrity of the film. During the 
manufacturing and storage of these dosage forms, special care, 
processing, and high-quality packaging are essentially required. The 
ideal characteristics for selecting packaging materials are: 
1. It should not get affected by the external environment.
2. It should be non-toxic.
3. It should be approved by the FDA.
4. It should not interact with the product.
5. It should meet the requirement of tamper-resistant [85].
Packaging for oral films generally includes foil, paper or plastic pouches, 
single pouch, aluminum pouch, blister cards with multiple units, and 
barrier films. Labtec GmbH formulated Rapid film technology which is 
a primary packaging made up of a sealing pouch having ample space 
for instructions, logos, codes, and other information. The laminating 
procedure was followed with an expense equal to that of tablets [86].
Foil, paper, or plastic pouches 
It is a kind of flexible pouch which provides tamper-resistance along 
with a proper selection of material, overall a package of a high degree of 
environmental protection. It is formed during the procedure of product 
filling by vertical or horizontal forming, filling, and sealing equipment. 
They are available as single pouches or aluminum pouches [85].
Single pouch and aluminum pouch
For a quick-dissolving soluble film, a peel able soluble film drug 
delivery pouch is used with high barrier properties. It is a transparent 
pouch for the visibility of the product. It has a two-dimensional 
structure out of which one side is clear and the other one has a 
low-cost lamination of foil. The foil lamination is restricted to the 
transmission of gas and moisture [85]. A single-dose pouch protects 
the dose as well as the product whereas an aluminum pouch is most 
commonly used [87].
Blister card with multiple units
The blister container is made up of two components: 1. Blister 2. Lid 
stock
Blister has a cavity made up of plastic material to protect it from 
moisture which holds the product and lid stock is a material made up 
of aluminum foil which seals to the blister. It is formed by softening a 
sheet of thermoplastic resin by providing heat and contour molding 
the softened plastic sheet under vacuum. The sheet is removed from 
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the mold after cooling and placed in the filling station of the packaging 
machine. The product is filled in the semi-rigid formed blister and 
sealed with a heat-sealable backing material as a lid stock [85].
Barrier films
Barrier films are generally required for those products which are 
highly sensitive to moisture. Certain materials which may protect from 
moisture are Poly chloro trifluoro ethylene (PCTFE) films, propylene. 
Propylene is a material that doesn’t crack under stress. It provides 
an excellent barrier to vapors and gas. The only drawback related to 
barrier films is the lack of clarity [85].
APPLICATIONS OF BUCCAL FILM
Vaccines
An alternative to buccal films can be in the form of a vaccine for its 
fast dissolving action in mouth and saliva which are stable at room 
temperature. One such example is the rotavirus vaccine manufactured 
in the United States which has certain advantages such as enhanced 
bioavailability, improved patient compliance with minimal cost related 
to storage, handling, and administration [88].
Controlled and sustained release
In hospital preparations and various excipients of polymers such as 
chitosan derivatives, sustained-release buccal films are applicable as 
it contributes to wound dressings, decreasing toxicity, and good water 
resisting and adhesive properties [88].
Nicotine replacement therapy (NRT)
Nicotine in tobacco is a psychoactive substance leading to the habitual 
nature of smoking. In this therapy, the mucosal route of delivery is the 
most efficient as it readily permeates into the mucosal membrane. 
Pongjanyakul et al. formulated sodium alginate-magnesium aluminum 
silicate (SA-MAS) buccal film with the incorporation of nicotine. The 
study showed that SA-MAS films provided with a higher content of 
nicotine and slower permeation across the membrane compared to 
only SA films. Initially, drug release was faster and after 10 h controlled 
drug release was observed [89].
Antifungal infections
Fluconazole, a systemic antifungal for therapy of oral candidiasis, is 
generally preferred for mucosal delivery. Its systemic side effects can 
be reduced by increasing its oral concentration. Through mucoadhesive 
buccal films of small doses of fluconazole, there was an increase in 
the contact time between the drug and pathogenic yeast for a longer 
duration which eventually increased its efficacy [90].
Management of herpes
For the management of oral herpetic lesions, an antiviral drug 
acyclovir is most widely used. The permeability of acyclovir is low in 
oral mucosa which results in reduced efficacy. Hence, a study by Nair 
et al. formulated nanoparticles by incorporating polymeric materials 
and was loaded into films. The results provided good mucoadhesive 
strength and great physicomechanical property with improved oral 
bioavailability of acyclovir [91].
Targeted therapy for oral cancer
The most approved treatment for oral cancer is the targeted therapy 
which aims for site-specific delivery with low levels of toxicity and 
side effects. By acquiring nano delivery systems in the form of films 
consisting of polymers, it has been concluded an increase in solubility, 
stability, and bioavailability accumulated even inside tumor cells. A 
study was conducted for the development of liposomes loaded in the 
film and was evaluated for its cytotoxicity in hematopoietic stem cells 
(HSC-3) [92].
Cardiovascular diseases
One of the major cardiovascular diseases that need to be under control 
with long-term therapy is hypertension. Antihypertensives such as 
carvedilol, propranolol, and metoprolol have a short half-life and low 
oral bioavailability due to poor aqueous solubility and high first-pass 
metabolism. To overcome this, the buccal mucoadhesive system was 
established as it provides a direct pathway into the systemic circulation 
through the internal jugular vein by preventing the first-pass effect of 
obtaining high bioavailability [93]. A lower effective dose of 3.125 mg 
of carvedilol produces higher efficacy with increasing contact time and 
bypassing the first-pass metabolism [94].
Hypoglycemic agents
Recently for hypoglycemic agents such as glipizide and glibenclamide 
buccal delivery system has been introduced. Administration of 2 or 3 
doses of 2.5–10 mg daily of glipizide leads to short biological half-life. 
Uptake of water by the film was seen when the water-insoluble drug 
was incorporated [95]. Different grades of HPMC with measured ratios 
were used for preparing glibenclamide mucoadhesive buccal films. In 
conclusion, buccal drug delivery can be useful in a controlled pattern 
at a low concentration of HPMC3000 [96]. Hypoglycemic activity has 
also been found in the fruit of Cucumis callosus belonging to family 
Cucurbitaceae [97].
Antiemetic
Ondansetron HCL shows certain properties such as low molecular 
weight and biphasic solubility that is an ideal characteristic for 
absorption through the buccal mucosa. Its bioavailability may get 
improved by the mucosal route as its primary route for clearance was 
through hepatic Phase I metabolism. Patients suffering from vomiting 
during chemotherapy find it difficult to swallow a tablet. Hence, it is 
justified that buccal film increases patient compliance by preventing 
the need for swallowing [98]. Nausea and vomiting associated with 
cancer chemotherapy is distinct from typical nausea and vomiting that 
many people experience in their normal daily life though the drugs used 
may be the same [99].
Asthma
The buccal patches have been formulated for delivery of sodium 
cromoglycate for treatment of asthma. The drug has short half-life and 
it was need to formulate it in a controlled release system. The results 
of inclusion of this drug in buccal patches led to extension of the time 
required to attain maximum concentration in the blood in addition 
to showing a reduction in the maximum plasma concentration in the 
blood. It also provided controlled release of the drug [100].
CONCLUSION
The present review concludes that the buccal film is that the most 
accurate and acceptable dosage form, due to higher patient compliance, 
faster drug delivery system, and bypasses the hepatic first-pass 
effect and shows enhance bioavailability. Buccal films will replace 
the conventional dosage forms, as well as fast disintegrating tablets 
due to its advantages over the conventional dosage forms, and they 
can be manufactured at a low cost. A range of dosage forms can be 
incorporate in buccal drug delivery. However, buccal films are more 
feasible formulation because of its simplicity in preparation, drug 
loading, and characterization. Buccal films will be a more robust 
choice to optimize the therapeutic efficacy of various API in the future. 
The oral mucoadhesive dosage forms can continue to be an exciting 
research focus on improving drug absorption, particularly for the new 
generation.
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